Skip to main content
Figure 4 | Journal for ImmunoTherapy of Cancer

Figure 4

From: Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Figure 4

High pretreatment frequency of mMDSC is associated with reduced OS. mMDSC frequencies were determined before (week 0/visit 1 (w0v1)), during (w8v5, w16v9 and w24v13) and after (follow-up (fu)) prostate GVAX/ipilimumab therapy by flow cytometry. A) A representative analysis of Lin?CD14+HLA-DR?/lo mMDSC. B) Percentage of mMDSC over follow-up. C) Kaplan meier curve for pre-treatment frequencies of mMDSC. Number of patients and corresponding median survival for each group are given. Differences between pre- and on- or post-treatment were analyzed with the repeated measures ANOVA with a post-hoc Dunnett's multiple comparisons test. Differences were considered significant when p?<?0.05, as indicated with asterisks (* p?<?0.05, ** p?<?0.01). Statistical significance of the survival distribution was analyzed by log-rank testing and indicated with the given p-value.

Back to article page